News
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
1d
MedPage Today on MSNCVS Drops Obesity Drug; Once-Weekly Growth Hormone; WeightWatchers' BankruptcyPeople prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...
The Most Favored Nation directive would allow drugmakers to directly sell their products to patients at a lower cost, cutting ...
CVS Health Corporation CVS and The Cigna Group CI shares trading lower Tuesday. President Donald Trump on Monday signed an ...
18h
Zacks.com on MSNLilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...
President Donald Trump's new health care initiative aims to reduce prescription drug costs by targeting pharmacy benefit managers, commonly known as PBMs.
In 2023, the Blue Shield of California announced that it was dropping CVS Caremark as its pharmacy benefit manager (PBM) and ...
Gov. Gavin Newsom will seek to regulate prescription drug intermediaries, eight months after vetoing a similar bill.
Iowa, suggested Congress could once again move to overhaul PBMs’ controversial business practices after legislators pass ...
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
13h
GlobalData on MSNNovo Nordisk taps Septerna in $2.2bn deal for oral obesity therapiesNovo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results